Sridhar K S, Ohnuma T, Plasse T F, Holland J F
Department of Neoplastic Diseases, Mt. Sinai School of Medicine, New York, New York.
Cancer. 1988 Oct 15;62(8):1577-81. doi: 10.1002/1097-0142(19881015)62:8<1577::aid-cncr2820620820>3.0.co;2-#.
Concurrent Cloning Efficiencies (CE) of both ascites and solid tumor samples from 36 patients with ovarian carcinoma were studied using the soft agar assay. The CE of both were highly variable (range, 0-1.234% and 0-0.802%, respectively). There was marked intrapatient and interpatient heterogeneity in the CE. Of the 36 tested, comparative CE were evaluable in 29. CE was 0 in both solid tumor and ascites in one patient. CE was 0 in four other ascites samples from four patients. In other 24, the relative CE of solid tumor/ascites from each patient ranged from 0.066 to 435. In the 29 patients with samples of ascites and a solid tumor evaluable for concurrent CE, the median colony counts of solid tumors was more than tenfold higher than ascites. The solid tumors obtained from 31 patients had a significantly higher CE than tumor cells obtained from ascites samples from 32 patients. Solid tumors were significantly better than ascites for in vitro testing based on the data that 75% (27/36) of solid tumors and only 31% (11/36) of ascites formed greater than or equal to 30 colonies. The drug sensitivity profiles of tumor cells from a solid tumor and ascites of the same patient appear similar. Based on these observations, it may be more cost and labor effective to do soft agar in vitro chemotherapy assays using a solid tumor than ascites in ovarian carcinoma.
采用软琼脂试验研究了36例卵巢癌患者腹水和实体瘤样本的同时克隆效率（CE）。两者的CE差异很大（范围分别为0 - 1.234%和0 - 0.802%）。CE在患者内和患者间均存在显著异质性。在36例检测患者中，29例可进行CE比较评估。1例患者的实体瘤和腹水的CE均为0。另外4例患者的4份腹水样本的CE为0。在其他24例中，每位患者实体瘤/腹水的相对CE范围为0.066至435。在29例可同时评估腹水和实体瘤样本CE的患者中，实体瘤的集落计数中位数比腹水高十倍以上。从31例患者获得的实体瘤的CE显著高于从32例患者腹水样本获得的肿瘤细胞。基于75%（27/36）的实体瘤和仅31%（11/36）的腹水形成大于或等于30个集落的数据，实体瘤在体外检测方面明显优于腹水。同一患者实体瘤和腹水的肿瘤细胞的药敏谱相似。基于这些观察结果，在卵巢癌中使用实体瘤进行软琼脂体外化疗试验可能比使用腹水更具成本效益和省力。
